Compare Infosys Limited (INFY) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Medpace Holdings Inc — how do they compare? Infosys Limited trades at $10.75 (market cap $41.74B), while Medpace Holdings Inc trades at $617.65 (market cap $16.82B). The key difference: Infosys Limited is far larger — about 2.5× Medpace Holdings Inc's market cap, and Infosys Limited pays a 4.89% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Medpace Holdings Inc for 14 Days on average.
| INFY | MEDP | |
|---|---|---|
Market Cap | $41.74B | $16.82B |
Volume | 31,354,285 | 223,093 |
Sector | Technology | Health |
52-Week High | $20.22 | $630.19 |
52-Week Low | $10.49 | $393.42 |
Typical Hold Time | 27 Days | 14 Days |
Enterprise Value | $39.48B | $16.44B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.75, up 1.9% in the last 24 hours, with a bearish technical signal from moving averages. The company reported a net income of $3.16B on $19.28B revenue for 2025, with profitability metrics like a 16.37% net margin and 32.12% ROE. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, to drive innovation. Earnings have been mixed, with beats in Q4 2025 and Q1 2026 but a miss in Q2 2026.
The outlook is cautious; while valuation ratios like a P/E of 13.21 appear reasonable and analyst consensus targets $11.48, weak IT spending and AI pricing pressure pose risks. Institutional sentiment is mixed with 35% buy ratings, but negative cash flow trends in 2026 forecast demand careful monitoring of execution against guidance.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
